These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26492223)

  • 1. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
    Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI
    Br J Cancer; 2015 Dec; 113(11):1571-80. PubMed ID: 26492223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 3. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
    Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
    Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
    J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
    Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
    Mir MH; Changal KH; Aziz SA; Bhat GM; Lone AR
    Int Urol Nephrol; 2016 Nov; 48(11):1811-1816. PubMed ID: 27448573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
    Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Hawkins RE; Crinò L; Kim TM; Carteni G; Eberhardt WE; Zhang K; Fly K; Matczak E; Lechuga MJ; Hariharan S; Bukowski R
    Br J Cancer; 2015 Jun; 113(1):12-9. PubMed ID: 26086878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
    Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study.
    Bolzacchini E; Pinotti G; Bertù L; Verusio C; Galli L; Mumoli N; Barbara C; Danova M; Bregni M; Artale S; Rossini C; Nigro O; Antonuzzo A; Derosa L; Torchio M; Barzaghi S; Ricci I; Suter M; Ballerio A; Vallini I; Dentali F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e145-e156. PubMed ID: 31889670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
    Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
    Fujita T; Iwamura M; Ishii D; Tabata K; Matsumoto K; Yoshida K; Baba S
    Int J Urol; 2012 Oct; 19(10):908-13. PubMed ID: 22671963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
    Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.
    Miyake H; Miyazaki A; Harada K; Fujisawa M
    Med Oncol; 2014 Jun; 31(6):978. PubMed ID: 24793747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
    BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.